November 5th, 2012
Selections from Richard Lehman’s Literature Review: November 5th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include fish consumption, omega-3 fatty acids, and cerebrovascular disease; HRT and cardiovascular disease in recently menopausal women; and more.
November 5th, 2012
Reclassifying AHA on the West Coast
Amit Shah, MD, MSCR
An evening epidemiology session highlights the value of AHA.12, as a fellow garners multiple insights from a series of speakers.
November 5th, 2012
AHA 2012 Headquarters
CardioExchange Editors, Staff
CardioExchange is dedicated to bringing you the latest from AHA 2012 and it can all be found right here.
November 4th, 2012
FREEDOM Lends Strong Support to CABG for Diabetics with Multivessel Disease
Larry Husten, PHD
CABG is associated with better cardiovascular outcomes than PCI in patients with diabetes and multivessel disease.
November 4th, 2012
NIH Trial Gives Surprising Boost to Chelation Therapy
Larry Husten, PHD
The TACT trial finds that cardiovascular endpoints were lower with chelation therapy than placebo in patients with prior MI, but trial investigators and others have expressed considerable caution about the proper interpretation of the results.
November 4th, 2012
Platelet-Function Testing in Coronary Stenting: Frozen in Its Tracks
Gilles Montalescot, MD, PhD
An ARCTIC trial investigator discusses possible reasons why antiplatelet-drug and dosing adjustments, guided by platelet-function testing, did not improve clinical outcomes for stented patients.
November 4th, 2012
AHA with Some Perspective
Reva Balakrishnan, MD, MPH
A fellow from NYU looks at the AHA through the lens of last year’s conference and her institution’s recent experience with Hurricane Sandy
November 4th, 2012
ARCTIC Blows a Cold Wind on Platelet Function Tests
Larry Husten, PHD
The use of platelet-function tests to monitor and guide antiplatelet therapy in PCI patients has sparked heated debate. Cardiologists have sought to reconcile biological plausibility with the absence of clinical evidence. Now the ARCTIC (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-Eluting Stent Implantation versus Continuation One […]
November 4th, 2012
ASPIRE: Aspirin an Attractive Alternative After First VTE
Larry Husten, PHD
It is unclear what the best approach is for the long-term treatment of people who have had a first unprovoked episode of venous thromboembolism (VTE). Although warfarin is effective at preventing a recurrence, it is inconvenient and raises the risk for bleeding. Newer anticoagulants have not been tested or approved for this population. The ASPIRE […]
November 4th, 2012
Management of Aortic Stenosis: Up Close and in Person
Megan Coylewright, MD MPH
An AHA.12 session on management of aortic stenosis includes an impressive line-up of experts and underscores the value of attending the meeting.
NEJM Journal Watch — Recent Cardiology Articles- Aficamten for Obstructive Hypertrophic Cardiomyopathy
- Obicetrapib and Cardiovascular Outcomes: Early Insights
- Statin Use in Pregnancy and Risk of Congenital Malformations
- More Data to Guide Anticoagulation After Ablation for Atrial Fibrillation
- Is Mavacamten Effective for Nonobstructive Hypertrophic Cardiomyopathy?